Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.49 |
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
| ▸ | EED | O75530 | 1/20 | 0.48 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.48 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.48 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.48 |
| ▸ | BTK | Q06187 | 4/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 11/20 | 0.45 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31198740 | 0.82 | GRM5 (0.52) | LNPEPGRM5EEDRBBP4SUZ12 | |
| SCHEMBL25428582 | 0.81 | LNPEP (0.47) | LNPEPGRM5BTKPTGDR2PRMT1 | |
| SCHEMBL26112816 | 0.80 | GRM5 (0.48) | LNPEPGRM5EEDRBBP4SUZ12 | |
| SCHEMBL8313387 | 0.80 | GRM5 (0.57) | LNPEPGRM5EEDRBBP4SUZ12 | |
| SCHEMBL31198721 | 0.79 | GRM5 (0.53) | LNPEPGRM5EEDRBBP4SUZ12 | |
| SCHEMBL13490526 | 0.79 | GRM5 (0.53) | LNPEPGRM5BTKPRMT1 | |
| SCHEMBL30852130 | 0.78 | PRMT1 (0.50) | LNPEPGRM5PTGDR2PRMT1 | |
| SCHEMBL8315932 | 0.77 | MEN1 (0.57) | LNPEPGRM5PRMT1 | |
| SCHEMBL31131365 | 0.77 | PTGDR2 (0.50) | LNPEPGRM5PTGDR2 | |
| SCHEMBL31298599 | 0.77 | GRM5 (0.51) | LNPEPGRM5EEDRBBP4SUZ12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855294-B2 | Cycloalkanopyridine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20070191419-A1 | Cycloalkanopyridine derivative | MSD K.K. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1726590-A1 | CYCLOALKANOPYRIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191419-A1 | Cycloalkanopyridine derivative | OPRL1, OPRK1, AVPR2 | LNPEP 443/4885GRM5 325/4885EED 3952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.